Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
IRWD

IRWD - Ironwood Pharmaceuticals Inc Stock Price, Fair Value and News

5.84USD-0.14 (-2.34%)Market Closed

Market Summary

IRWD
USD5.84-0.14
Market Closed
-2.34%

IRWD Alerts

  • 6 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

IRWD Stock Price

View Fullscreen

IRWD RSI Chart

IRWD Valuation

Market Cap

928.3M

Price/Earnings (Trailing)

-0.88

Price/Sales (Trailing)

2.24

EV/EBITDA

-1.03

Price/Free Cashflow

6.28

IRWD Price/Sales (Trailing)

IRWD Profitability

Operating Margin

95.38%

EBT Margin

-243.98%

Return on Equity

318.32%

Return on Assets

-239.76%

Free Cashflow Yield

15.93%

IRWD Fundamentals

IRWD Revenue

Revenue (TTM)

413.6M

Rev. Growth (Yr)

-28.05%

Rev. Growth (Qtr)

-36.3%

IRWD Earnings

Earnings (TTM)

-1.1B

Earnings Growth (Yr)

-109.1%

Earnings Growth (Qtr)

-282.89%

Breaking Down IRWD Revenue

Last 7 days

-8.0%

Last 30 days

-11.0%

Last 90 days

-35.2%

Trailing 12 Months

-47.0%

How does IRWD drawdown profile look like?

IRWD Financial Health

Current Ratio

0.82

Debt/Equity

-0.6

Debt/Cashflow

0.75

IRWD Investor Care

Shares Dilution (1Y)

2.32%

Diluted EPS (TTM)

-6.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024413.6M000
2023417.1M427.3M432.4M442.7M
2022422.4M415.6M420.5M410.6M
2021398.4M413.0M413.3M413.8M
2020439.6M426.8M399.1M389.5M
2019343.0M364.1M436.0M428.4M
2018315.3M331.3M303.8M343.4M
2017260.1M270.8M291.5M298.3M
2016186.7M213.3M239.8M274.0M
201590.8M111.7M134.3M149.6M
201434.2M31.4M43.4M76.4M
2013118.4M86.6M54.7M22.9M
201267.9M71.2M155.4M150.2M
201145.3M47.3M50.5M65.9M
201036.7M39.1M41.5M43.9M
200900034.3M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ironwood Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
mchugh julie
sold
-143,198
6.29
-22,766
-
Jun 07, 2024
moukheibir catherine
sold
-235,144
6.61
-35,574
-
Jun 06, 2024
moukheibir catherine
sold
-282,549
6.36
-44,426
-
May 20, 2024
shetzline michael
sold
-104,026
6.45
-16,128
cmo,svp,head-res&drug
May 20, 2024
mccourt thomas a
sold
-436,136
6.45
-67,618
chief executive officer
May 20, 2024
davis andrew
sold
-146,576
6.45
-22,725
svp, chief business officer
May 20, 2024
john minardo
sold
-112,256
6.45
-17,404
chief legal officer
May 16, 2024
emany sravan kumar
sold (taxes)
-242,758
6.64
-36,560
svp, chief financial officer
Mar 15, 2024
denner alexander j
acquired
-
-
1,662
-

1–10 of 50

Which funds bought or sold IRWD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 29, 2024
Clean Yield Group
unchanged
-
-232
740
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-121,000
386,000
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
113,230
113,230
-%
May 24, 2024
Cetera Investment Advisers
new
-
36,476
36,476
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.61
55,093
262,093
0.03%
May 20, 2024
EMC Capital Management
reduced
-44.84
-288,000
208,000
0.12%
May 17, 2024
Artal Group S.A.
unchanged
-
-301,266
962,734
0.03%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.4
-462,469
1,236,980
-%
May 16, 2024
COMERICA BANK
reduced
-10.73
-203,034
430,788
-%
May 16, 2024
Virtus Investment Advisers, Inc.
unchanged
-
-57,802
184,417
0.13%

1–10 of 40

Are Funds Buying or Selling IRWD?

Are funds buying IRWD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IRWD
No. of Funds

Unveiling Ironwood Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2024
lsv asset management
4.35%
6,793,701
SC 13G/A
Jan 25, 2024
state street corp
7.39%
11,532,088
SC 13G/A
Jan 22, 2024
blackrock inc.
16.6%
25,978,899
SC 13G/A
Jan 10, 2024
vanguard group inc
10.27%
16,033,545
SC 13G/A
Jul 05, 2023
westfield capital management co lp
-
0
SC 13G/A
May 10, 2023
wellington management group llp
0.00%
0
SC 13G/A
Feb 14, 2023
brown capital management llc
2.61%
3,997,045
SC 13G/A
Feb 10, 2023
lsv asset management
5.17%
7,926,397
SC 13G
Feb 09, 2023
vanguard group inc
9.60%
14,732,569
SC 13G/A
Feb 06, 2023
wellington management group llp
8.70%
13,340,377
SC 13G/A

Recent SEC filings of Ironwood Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 12, 2024
4
Insider Trading
Jun 10, 2024
144
Notice of Insider Sale Intent
Jun 10, 2024
4
Insider Trading
Jun 07, 2024
144
Notice of Insider Sale Intent
Jun 06, 2024
144
Notice of Insider Sale Intent
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading

Peers (Alternatives to Ironwood Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.3B
85.6B
-4.67% -11.11%
9.1
4.09
5.68% 202.39%
327.9B
61.4B
-1.72% 18.35%
142.2
5.34
6.11% -82.30%
160.2B
29.5B
-6.40% 30.72%
42.57
5.42
12.76% -52.47%
156.0B
35.0B
-4.48% -30.74%
134.25
4.45
-26.40% -92.03%
81.1B
27.4B
-2.90% -17.63%
167.32
2.95
1.51% -91.32%
19.3B
16.0B
2.21% 126.25%
-38.95
1.2
7.23% 71.10%
MID-CAP
4.1B
1.7B
1.49% -23.27%
9.54
2.4
54.01% 364.56%
3.7B
4.6B
-11.15% -22.04%
-475.35
0.8
-0.06% 94.55%
2.3B
9.0B
-10.73% -15.05%
-5.09
0.26
10.01% -27.45%
2.0B
676.2M
-4.67% -22.53%
12.79
2.93
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-18.36% 4.97%
-3.72
1.76
24.65% 80.36%
23.5M
1.3M
-2.39% -46.88%
-3.18
18.07
-98.14% -104.71%
18.0M
89.6M
-7.83% -14.52%
-1.27
0.19
287.27% -129.41%
2.4M
21.5M
-7.89% -89.23%
-0.31
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Ironwood Pharmaceuticals Inc News

Latest updates
Defense World17 hours ago

Ironwood Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-36.3%75.0011811410710410710997.0098.0011710410489.0011710389.0080.0012613110269.00
Costs and Expenses-20.1%64.0080.0074.001,19144.0039.0040.0042.0040.0061.0039.0039.0043.0065.0058.0057.0067.0077.0065.0081.0086.00
Operating Expenses-----44.00-40.0042.0040.00-39.0039.0043.00--------
  S&GA Expenses-2.7%38.0039.0036.0052.0031.0028.0029.0030.0029.0029.0028.0027.0028.0034.0035.0035.0036.0039.0041.0043.0049.00
  R&D Expenses-27.6%26.0036.0033.0035.0013.0010.0012.0011.0011.0032.0011.0012.0015.0016.0022.0022.0028.0027.0028.0029.0032.00
EBITDA Margin-13.4%-2.37*-2.09*-2.06*-2.01*0.65*0.64*0.58*0.57*0.58*0.56*0.56*0.50*---------
Interest Expenses-14.2%7.008.0010.002.002.002.002.002.002.008.008.008.008.008.007.007.007.007.0010.009.0010.00
Income Taxes-71.7%9.0032.0018.0013.0020.0023.0020.0017.0018.005.004.00-3360.001.001.00------
Earnings Before Taxes-83.7%5.0030.0032.00-1,07666.0072.0070.0054.0056.0046.0060.0054.0040.0045.0036.0025.003.0048.0021.00--
EBT Margin-13.9%-2.44*-2.14*-2.10*-2.03*0.63*0.61*0.54*0.52*0.51*0.48*0.48*0.42*---------
Net Income-282.9%-4.16-1.0915.00-1,06246.0049.0050.0037.0039.0041.0056.0039140.0043.0034.0025.003.0048.0021.0012.00-59.28
Net Income Margin-12.4%-2.54*-2.26*-2.20*-2.15*0.44*0.43*0.40*0.42*1.25*1.28*1.28*1.23*---------
Free Cashflow26.1%45.0036.0032.0035.0080.0079.0069.0061.0064.0064.0075.0049.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-6.8%4394715246031,1551,1011,0409761,0831,1271,0791,007599559492444404403334316324
  Current Assets-10.8%208233254318866781699618710745695620538496433374334307258221202
    Cash Equivalents31.9%12292.0011017574065857450459362057449343836530825323117913999.00119
  Inventory------------------1.002.002.001.00
  Net PPE-5.3%5.006.006.006.006.006.007.007.007.008.008.008.009.009.009.0011.0012.0012.0011.007.0010.00
  Goodwill------------------1.001.001.001.00
  Current Liabilities-8.6%25227628130524.0026.0027.0023.0014716214613424.0032.0033.0027.0028.0041.0053.00111119
  Long Term Debt0.1%198198198198397396396395395337333329436430425419413408403274270
    LT Debt, Current0.1%200200199199----121117115113---------
    LT Debt, Non Current0.1%198198198198397396396395395337333329436430425419413408403274270
Shareholder's Equity4.6%-330-346--70765259153351860658051211063.006.00------
  Retained Earnings-0.2%-1,702-1,698-1,697-1,712-650-696-745-795-832-937-978-1,034-1,426-1,466-1,509-1,543-1,568-1,572-1,620-1,640-1,650
  Additional Paid-In Capital1.3%1,3731,3551,3751,3671,3571,3491,3361,3281,3501,5431,5591,5461,5361,5291,5151,5071,4971,4791,4671,4211,413
Shares Outstanding1.7%159156156156154154155156158162162162---------
Minority Interest----2.46-1.07-----------------
Float----1,466---1,555---1,859---1,635---1,697-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations25.5%44,98535,83432,45934,96380,17179,18269,09261,36564,12464,56875,06548,56873,69451,51353,63220,08843,60327,58034,767-9,237-42,385
  Share Based Compensation-3.7%8,3858,7047,9068,2647,1317,2917,0676,6016,0896,0906,2064,5895,39610,0087,7127,0916,3645,4865,5206,33713,934
Cashflow From Investing98.4%-68.00-4,188-22,625-999,492-13.0027.00-66.00-88.00-9.00-128----28.00--376-1,438-2,661-3,077-2,429-2,977
Cashflow From Financing69.4%-15,555-50,904-74,988399,0713,9812,806797-150,283-90,873-18,5876,1645,6622,2113,5246702,39711,9556,4478,633-7,500-8,765
  Buy Backs----32,90090,500-1,50532,89690,489------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

IRWD Income Statement

2024-03-31
Condensed Consolidated Statements of Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 74,877$ 104,061
Revenue from Contract with Customer, Product and ServiceCollaborative arrangements revenueCollaborative arrangements revenue
Costs and expenses:  
Research and development$ 25,815$ 12,847
Selling, general and administrative37,60531,117
Restructuring expenses437 
Total costs and expenses63,85743,964
Income from operations11,02060,097
Other income (expense):  
Interest expense and other financing costs(7,231)(1,527)
Interest and investment income1,1697,272
Gain on derivatives 19
Other income (expense), net(6,062)5,764
Income before income taxes4,95865,861
Income tax expense(9,120)(20,147)
Net income (loss)$ (4,162)$ 45,714
Net income (loss) per share - basic (in dollars per share)$ (0.03)$ 0.30
Net income (loss) per share - diluted (in dollars per share)$ (0.03)$ 0.25
Weighted average shares used in computing net income (loss) per share - basic (in shares)157,700154,452
Weighted average shares used in computing net income (loss) per share - diluted (in shares)157,700186,680

IRWD Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 121,540$ 92,154
Accounts receivable, net72,015129,122
Prepaid expenses and other current assets14,61912,012
Total current assets208,174233,288
Property and equipment, net5,2885,585
Operating lease right-of-use assets12,20812,586
Intangible assets, net3,4783,682
Deferred tax assets206,273212,324
Other assets3,3983,608
Total assets438,819471,073
Current liabilities:  
Accounts payable6,2227,830
Accrued research and development costs11,88021,331
Accrued expenses and other current liabilities31,39844,254
Current portion of operating lease liabilities3,1423,126
Current portion of convertible senior notes199,800199,560
Total current liabilities252,442276,101
Convertible senior notes, net of current portion198,477198,309
Operating lease obligations, net of current portion14,00414,543
Revolving credit facility275,000300,000
Other liabilities29,41428,415
Commitments and contingencies
Stockholders' equity (deficit):  
Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 158,957,123 shares issued and outstanding at March 31, 2024 and 500,000,000 shares authorized and 156,354,238 shares issued and outstanding at December 31, 2023159156
Additional paid-in capital1,373,0221,355,195
Accumulated deficit(1,702,777)(1,698,615)
Accumulated other comprehensive loss(922)(3,031)
Total stockholders' deficit(330,518)(346,295)
Total liabilities and stockholders' deficit$ 438,819$ 471,073
IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEironwoodpharma.com
 INDUSTRYPharmaceuticals
 EMPLOYEES219

Ironwood Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Ironwood Pharmaceuticals Inc? What does IRWD stand for in stocks?

IRWD is the stock ticker symbol of Ironwood Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ironwood Pharmaceuticals Inc (IRWD)?

As of Fri Jun 14 2024, market cap of Ironwood Pharmaceuticals Inc is 928.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IRWD stock?

You can check IRWD's fair value in chart for subscribers.

What is the fair value of IRWD stock?

You can check IRWD's fair value in chart for subscribers. The fair value of Ironwood Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ironwood Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IRWD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ironwood Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IRWD is over valued or under valued. Whether Ironwood Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ironwood Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IRWD.

What is Ironwood Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, IRWD's PE ratio (Price to Earnings) is -0.88 and Price to Sales (PS) ratio is 2.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRWD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ironwood Pharmaceuticals Inc's stock?

In the past 10 years, Ironwood Pharmaceuticals Inc has provided -0.075 (multiply by 100 for percentage) rate of return.